10.15131/shef.data.11914158.v1
Shijie Ren
Shijie
Ren
Katy Cooper
Katy
Cooper
James Cooper
James
Cooper
Helen Smith
Helen
Smith
Soraya Shaikh
Soraya
Shaikh
A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014)
The University of Sheffield
2020
pharmacological therapy
parkinson
Health Economics
2020-03-01 16:17:54
Poster
https://orda.shef.ac.uk/articles/poster/A_systematic_review_and_network_meta_-_analysis_of_pharmacological_therapies_used_for_patients_with_advanced_Parkinson_s_disease_2014_/11914158
<p>Parkinson’s disease affects about 110,000 people in the UK
and 1.25 million people in Europe.1
Current options for management of advanced Parkinson’s disease include: </p>
<p>• Increased dose or frequency of immediate-release levodopa
(IR LD)</p>
<p> • Supplemental
controlled-release levodopa (CR LD)</p>
<p> • Adjunctive
therapies with levodopa, including dopamine agonists, monoamine oxidase-B
inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A
new modified release form of levodopa (IPX066) is in development. </p>